Seung-Yun Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seung-Yun Cho has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Jong-Won Ha
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
3 shared publications - Byoung Wook Choi
Department of Radiology, Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2 shared publications Namsik Chung
Division of Cardiology, Severeance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
2 shared publications- Namsik Chung
Division of Cardiology, Yonsei Cardiovascular Center, Yonsei University College of Medicine, Seoul, Republic of Korea
2 shared publications - Se-Joong Rim
Division of Cardiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2 shared publications - Won-Heum Shim
Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- 1 July 2014
- Published by Elsevier in Journal of Cardiology Cases
- Vol. 10 (1) , 9-12
Abolished ischemic tricuspid regurgitation by revascularization of left anterior descending artery: The role of collateral circulation
- 1 July 2014
- Published by Elsevier in Journal of Cardiology Cases
- Vol. 10 (1) , 9-12
Abolished ischemic tricuspid regurgitation by revascularization of left anterior descending artery: The role of collateral circulation
- 1 June 2012
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 12 (3) , 189-195
Comparison of the Efficacy and Safety of Fixed-Dose Amlodipine/Losartan and Losartan in Hypertensive Patients Inadequately Controlled with Losartan
Fixed-dose combination drugs may enhance blood pressure (BP) goal attainment through complementary effects and reduced side effects, which leads to better compliance. This study aimed to evaluate the efficacy and safety profiles of once-daily combination amlodipine/losartan versus losartan. This was an 8-week, double-blind, multicenter, randomized phase III study conducted in outpatient hospital clinics. Korean patients with essential hypertension inadequately controlled on losartan 100 mg were administered amlodipine/losartan 5 mg/100 mg combination versus losartan 100 mg. The main outcome measures were changes in sitting diastolic blood pressure (DBP) and sitting systolic blood pressure (SBP) and BP response rate from baseline values, which were assessed after 4 and 8 weeks of treatment. Safety and tolerability were also assessed. At week 8, both groups achieved significant reductions from baseline in DBP (11.7 ± 7.0 and 3.2 ±7.9 mmHg), which was significantly greater in the amlodipine/losartan 5 mg/100 mg combination (n = 70) group (p < 0.0001). Additionally, the amlodipine/losartan 5 mg/100 mg combination group achieved significantly greater reductions in SBP at week 8 and in SBP and DBP at week 4 compared with the losartan 100 mg (n = 72) group (all p<0.0001). Response rates were significantly higher in the amlodipine/losartan 5 mg/100 mg group versus the losartan 100 mg group (81.4% vs 63.9% at week 4, p < 0.0192; 90.0% vs 66.7% at week 8, p<0.001). Both treatments were generally well tolerated. Switching to a fixed-dose combination therapy of amlodipine/losartan 5 mg/100 mg was associated with significantly greater reductions in BP and superior achievement of BP goals compared with a maintenance dose of losartan 100 mg in Korean patients with essential hypertension inadequately controlled on losartan 100 mg. Registered at Clinicaltrials.gov as NCT00940680.
- 1 June 2012
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 12 (3) , 189-195
Comparison of the Efficacy and Safety of Fixed-Dose Amlodipine/Losartan and Losartan in Hypertensive Patients Inadequately Controlled with Losartan
Fixed-dose combination drugs may enhance blood pressure (BP) goal attainment through complementary effects and reduced side effects, which leads to better compliance. This study aimed to evaluate the efficacy and safety profiles of once-daily combination amlodipine/losartan versus losartan. This was an 8-week, double-blind, multicenter, randomized phase III study conducted in outpatient hospital clinics. Korean patients with essential hypertension inadequately controlled on losartan 100 mg were administered amlodipine/losartan 5 mg/100 mg combination versus losartan 100 mg. The main outcome measures were changes in sitting diastolic blood pressure (DBP) and sitting systolic blood pressure (SBP) and BP response rate from baseline values, which were assessed after 4 and 8 weeks of treatment. Safety and tolerability were also assessed. At week 8, both groups achieved significant reductions from baseline in DBP (11.7 ± 7.0 and 3.2 ±7.9 mmHg), which was significantly greater in the amlodipine/losartan 5 mg/100 mg combination (n = 70) group (p < 0.0001). Additionally, the amlodipine/losartan 5 mg/100 mg combination group achieved significantly greater reductions in SBP at week 8 and in SBP and DBP at week 4 compared with the losartan 100 mg (n = 72) group (all p<0.0001). Response rates were significantly higher in the amlodipine/losartan 5 mg/100 mg group versus the losartan 100 mg group (81.4% vs 63.9% at week 4, p < 0.0192; 90.0% vs 66.7% at week 8, p<0.001). Both treatments were generally well tolerated. Switching to a fixed-dose combination therapy of amlodipine/losartan 5 mg/100 mg was associated with significantly greater reductions in BP and superior achievement of BP goals compared with a maintenance dose of losartan 100 mg in Korean patients with essential hypertension inadequately controlled on losartan 100 mg. Registered at Clinicaltrials.gov as NCT00940680.
- 19 July 2005
- Published by Wolters Kluwer Health in Circulation
- Vol. 112 (3) , e49-50
Extensive Subepicardial Fibrosis in a Patient With Apical Hypertrophic Cardiomyopathy With Persistent ST-Segment Elevation Simulating Acute Myocardial Infarction
- 19 July 2005
- Published by Wolters Kluwer Health in Circulation
- Vol. 112 (3) , e49-50
Extensive Subepicardial Fibrosis in a Patient With Apical Hypertrophic Cardiomyopathy With Persistent ST-Segment Elevation Simulating Acute Myocardial Infarction
- 31 May 2005
- Published by Wolters Kluwer Health in Circulation
- Vol. 111 (21) , 365-366
Constrictive Epicarditis as an Unusual Cause of Constrictive Physiology
- 31 May 2005
- Published by Wolters Kluwer Health in Circulation
- Vol. 111 (21) , 365-366
Constrictive Epicarditis as an Unusual Cause of Constrictive Physiology